Khosla Ventures

Khosla Ventures is a venture capital firm established in 2004 by Vinod Khosla, a co-founder of Sun Microsystems. Based in Menlo Park, California, the firm manages over $5 billion and primarily invests in early-stage technology companies throughout the United States. Khosla Ventures provides capital, strategic advice, and venture assistance to entrepreneurs focused on breakthrough innovations across various sectors, including consumer technology, enterprise solutions, health, education, agriculture, and sustainable energy. The firm has a particular interest in high-risk, high-reward opportunities, often acting as a sole investor in "science or innovation experiments." Investment sizes typically range from $100,000 to over $20 million, allowing Khosla Ventures to support both traditional ventures and unconventional projects.

Bruce Armstrong

Operating Partner

Irene Au

Angel

Ryno Blignaut

Operating Partner

Alice Brooks

Partner

Peter Buckland

Partner, Managing Director and COO

Benny Buller

Investment Professional

Brian Byun

Operating Partner

Catherine Casuga

Operating Partner

Kanu Gulati

Partner

Emmanuel T. Hernandez

Operating Partner

Judy Huang

Operating Partner

Keith Janosky

Chief Financial Officer and Head of Investor Relations

Jun Jeon

Principal

Samir Kaul

Founding Partner & Managing Director

Paul Kirincich

Operating Partner

Alexander A. Morgan

Partner

Alexander Morgan Ph.D

Partner

Hesam Motlagh

Chief of Staff

Keith Rabois

Managing Director

Nikita Shamgunov

Partner & Investor

Sven Strohband Ph.D

Managing Director

Rajesh Swaminathan

Partner

Adina Tecklu

Partner

Sandhya Venkatachalam

Partner

David Weiden

Founding Partner and Managing Director

Ece Wyrick

Principal

Past deals in Dietary Supplements

Joywell Foods

Series B in 2022
Derived from exotic plants, protein sweeteners are rare compounds that provide an amazing taste without the calories.

Faeth

Seed Round in 2022
Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

Joywell Foods

Series A in 2020
Derived from exotic plants, protein sweeteners are rare compounds that provide an amazing taste without the calories.

BioAge Labs

Series B in 2019
BIOAGE discovers and develops drugs to treat aging and associated diseases.